Antipsychotic drugs in schizophrenia: current issues.

No abstract is available for this paper.

• Publication year

  1988

• Venue

  International Clinical Psychopharmacology

• Publication date

  Unknown publication date

• Fields of study

  Medicine, Psychology

• Identifiers
  DOI 10.1097/00004850-198801000-00001PMID 2895785
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• EFFECT OF CHLORPROMAZINE OR HALOPERIDOL ON FORMATION OF 3METHOXYTYRAMINE AND NORMETANEPHRINE IN MOUSE BRAIN.

  2009cited by this paper
• Mesolimbic dopamine function is not altered during continuous chronic treatment of rats with typical or atypical neuroleptic drugs

  2005cited by this paper
• Neuroleptic-induced hypersensitivity of striatal dopamine receptors in the rat as a model of tardive dyskinesias. Effects of clozapine, haloperidol, loxapine and chlorpromazine

  2004cited by this paper
• Long-term neuroleptic treatment of chronic schizophrenic patients: Clinical and biochemical effects of withdrawal

  2004cited by this paper
• High dosage haloperidol therapy in chronic schizophrenic patients: A double-blind study of clinical response, side effects, serum haloperidol, and serum prolactin

  2004cited by this paper
• High doses of diazepam improve neuroleptic-resistant chronic schizophrenic patients

  2004cited by this paper
• The importance of dosage in antipsychotic drug administration — A review of dose-response studies

  2004cited by this paper
• Fluphenazine pharmacokinetics and therapeutic response

  2004cited by this paper
• Chlorpromazine in chronic schizophrenia: Behavioral dose-response relationships

  2004cited by this paper
• Clinical response and plasma haloperidol levels in schizophrenia

  2004cited by this paper
• Supersensitivity psychosis in schizophrenic patients after sudden clozapine withdrawal

  2004cited by this paper
• Antipsychotic drugs in schizophrenia: current issues.

  1988cited by this paper
• Tiaspirone in schizophrenia.

  1987cited by this paper
• Combination alprazolam-neuroleptic treatment of the positive and negative symptoms of schizophrenia.

  1986cited by this paper
• Low dose maintenance medication for schizophrenia

  1986cited by this paper
• Pharmacology of antipsychotic drugs.

  1985cited by this paper
• New antipsychotic agents and the future.

  1985cited by this paper
• Possible mechanisms by which repeated clozapine administration differentially affects the activity of two subpopulations of midbrain dopamine neurons

  1985cited by this paper
• Acute and subchronic effects of MJ-13859, a potential antipsychotic drug, on rat brain dopaminergic function.

  1985cited by this paper
• Problems in Classification of Schizophrenics as Neuroleptic Responders and Nonresponders

  1985cited by this paper
• Plasma levels of haloperidol and clinical response.

  1985cited by this paper
• Commentary: The Strategy and Value of Neuroleptic Drug Monitoring

  1985cited by this paper
• Familial differences in lithium responsive versus lithium nonresponsive psychoses.

  1985cited by this paper
• Carbamazepine-induced reduction of blood levels of haloperidol in chronic schizophrenia.

  1985cited by this paper
• The interpretation of plasma haloperidol concentrations.

  1985cited by this paper
• Absence of relationship of serum haloperidol concentration and clinical response in chronic schizophrenia: a fixed-dose study.

  1985cited by this paper
• Plasma haloperidol levels: clinical response and fancy mathematics.

  1985cited by this paper
• Dissimilar dosing with high-potency and low-potency neuroleptics.

  1984cited by this paper
• Carbamazepine and haloperidol v placebo and haloperidol in excited psychoses. A controlled study.

  1984cited by this paper
• Neuroleptic concentrations and clinical response.

  1984cited by this paper
• Psychosis after neuroleptic withdrawal in a manic-depressive patient.

  1984cited by this paper
• The use of depot neuroleptics: clinical experience in the United States.

  1984cited by this paper
• Mood-incongruent versus mood-congruent psychosis: differential antipsychotic response to lithium therapy.

  1984cited by this paper
• Membrane abnormalities in the psychoses and affective disorders.

  1984cited by this paper
• Therapeutic blood levels of fluphenazine: plasma or RBC determinations?

  1984cited by this paper
• Depot neuroleptics: the relevance of psychosocial factors--a United States perspective.

  1984cited by this paper
• Rapid tranquilization: a comparative study of thiothixene and haloperidol.

  1984cited by this paper
• The relationship between haloperidol blood levels and clinical responses.

  1984cited by this paper
• Costs and benefits of two doses of fluphenazine.

  1984cited by this paper
• Future of depot neuroleptic therapy: pharmacokinetic and pharmacodynamic approaches.

  1984cited by this paper
• High-Dose Neuroleptics: Uncontrolled Clinical Practice Confirms Controlled Clinical Trials

  1984cited by this paper
• Effects of high and low dosage of haloperidol on the brain in relation to schizophrenic thought disorder.

  1984cited by this paper
• Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons.

  1983cited by this paper
• A controlled study of neuroleptization with fluphenazine hydrochloride injections.

  1983cited by this paper
• Neuroleptics have identical potencies in human brain limbic and putamen regions.

  1983cited by this paper
• Therapeutic window for plasma haloperidol in acute schizophrenic psychosis.

  1983cited by this paper
• Low-dose neuroleptic treatment of outpatient schizophrenics. I. Preliminary results for relapse rates.

  1983cited by this paper
• Hypothalamic dopamine receptor supersensitivity? A pilot study of self-induced water intoxication.

  1983cited by this paper
• The discontinuance of maintenance neuroleptic therapy in chronic schizophrenic patients: drug and social consequences

  1983cited by this paper
• Reserpine withdrawal psychosis: the possible role of denervation supersensitivity of receptors.

  1982cited by this paper
• Growth hormone levels and lithium ratios as predictors of success of lithium therapy in schizophrenia.

  1982cited by this paper
• Fluphenazine blood levels and clinical response.

  1982cited by this paper
• Intensive treatment with haloperidol of treatment-resistant chronic schizophrenic patients.

  1982cited by this paper
• High neuroleptic plasma levels in patients manifesting supersensitivity psychosis.

  1982cited by this paper
• RBC and plasma levels of haloperidol and clinical response in schizophrenia.

  1982cited by this paper
• Relationship of serum haloperidol levels to clinical response in schizophrenic patients.

  1981cited by this paper
• Drug withdrawal in chronic schizophrenic patients: in search of neuroleptic-induced supersensitivity psychosis.

  1981cited by this paper
• Physostigmine and lithium response in the schizophrenias.

  1981cited by this paper
• Is maintenance neuroleptic therapy necessary in shallow hebephrenia.

  1981cited by this paper
• Rapid treatment of acute psychotic symptoms with high- and low-dose haloperidol. Behavioral considerations.

  1981cited by this paper
• Chlorpromazine levels and the outcome of treatment in schizophrenic patients.

  1981cited by this paper
• A depot neuroleptic withdrawal study

  1981cited by this paper
• Site-specific blockade of dopamine receptors by neuroleptic agents in human brain.

  1981cited by this paper
• Computerized EEG as a Predictor of Drug Response in Treatment Resistant Schizophrenics

  1981cited by this paper
• Mesoridazine -- a pharmacodynamic and pharmacokinetic profile.

  1981cited by this paper
• Substituted benzamide drugs as selective neuroleptic agents.

  1981cited by this paper
• Tardive Dyskinesia and Hospital Discharge

  1980cited by this paper
• Lack of behavioral supersensitivity to d-amphetamine after pimozide withdrawal. A trial with schizophrenic patients.

  1980cited by this paper
• Lithium response in good prognosis schizophrenia.

  1980cited by this paper
• Clinical State, Plasma Levels of Haloperidol and Prolactin: A Correlation Study in Chronic Schizophrenia

  1980cited by this paper
• Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics.

  1980cited by this paper
• Serum haloperidol determinations in psychiatric patients. Comparison of methods and correlation with serum prolactin level.

  1980cited by this paper
• What is the best maintenance dose of neuroleptics in schizophrenia?

  1980cited by this paper
• Haloperidol for acute schizophrenic patients. An evaluation of three oral regimens.

  1980cited by this paper
• Controlled Trial of Sulpiride in Chronic Schizophrenic Patients

  1980cited by this paper
• Amantadine reduces haloperidol-induced dopamine receptor hypersensitivity in the striatum.

  1980cited by this paper
• Antischizophrenic drugs: differential plasma protein binding and therapeutic activity.

  1979cited by this paper
• Comparison of sulpiride and chlorpromazine in psychoses

  1979cited by this paper
• Factors related to tardive dyskinesia.

  1979cited by this paper
• Neuroendocrine Effects of Apomorphine: Characterization of Response Patterns and Application to Schizophrenia Research

  1979cited by this paper
• Serum levels of neuroleptics measured by dopamine radioreceptor assay and some clinical observations.

  1979cited by this paper
• Drug and family therapy in the aftercare of acute schizophrenics.

  1978cited by this paper
• Clinical effects and drug concentrations in plasma and cerebrospinal fluid in psychotic patients treated with fixed doses of chlorpromazine

  1978cited by this paper
• Schizophrenic symptoms improve with apomorphine.

  1978cited by this paper
• Tardive dyskinesia during and following treatment with haloperidol, haloperidol + biperiden, thioridazine, and clozapine

  1978cited by this paper
• High vs standard dosage fluphenazine HCL in acute schizophrenia.

  1978cited by this paper
• "Akinetic depression" in schizophrenia.

  1978cited by this paper
• Classification of neuroleptic drugs according to their ability to inhibit apomorphine-induced locomotion and gnawing: Evidence for two different mechanisms of action

  1978cited by this paper
• Long-term treatment with lithium prevents the development of dopamine receptor supersensitivity.

  1978cited by this paper
• Schizophrenia following Withdrawal from Chronic Phenothiazine Administration: A Case Report*

  1978cited by this paper
• Low plasma levels of CPZ in patients chronically treated with neuroleptics.

  1978cited by this paper
• Plasma Level Monitoring of Antipsychotic Drugs

  1978cited by this paper
• Sulpiride: evaluation of antipsychotic activity in schizophrenic patients.

  1977cited by this paper
• Dopaminergic supersensitivity in striatum and olfactory tubercle following chronic administration of haloperidol or clozapine.

  1977cited by this paper
• Pharmacokinetics of chlorpromazine after single and chronic dosage

  1977cited by this paper
• Regional effects of neuroleptics on dopamine metabolism and dopamine-sensitive adenylate cyclase activity.

  1977cited by this paper
• Dopamine metabolism in the nucleus accumbens: the effect of clozapine.

  1976cited by this paper
• Differential effect of neuroleptic drugs on dopamine turnover in the extrapyramidal and limbic system

  1976cited by this paper
• Regional rat brain levels of 3,4-dihydroxyphenylacetic acid and homovanillic acid: concurrent fluorometric measurement and influence of drugs.

  1976cited by this paper
• Maintenance antipsychotic therapy: is the cure worse than the disease?

  1976cited by this paper

• THERAPEUTIC DRUG MONITORING IN SALIVA

  2020cites this paper
• Adverse effects of long‐term administration of fluvoxamine on haematology, blood biochemistry and fertility in male albino rats: a possible effect of cessation

  2016cites this paper
• Benzisoxazole derivatives as Atypical Antipsychotic drugs: A Review

  2014cites this paper
• Prospective Predictors of Premature Death: Evidence from the National Longitudinal Study of Adolescent Health

  2010cites this paper
• [Experimental approaches to perceptual dysfunction in schizophrenia].

  2003cites this paper
• Aproximaciones experimentales a la disfunción perceptual en la esquizofrenia

  2003cites this paper
• MECHANISM OF ACTION OF ATYPICAL ANTIPSYCHOTIC DRUGS

  2002cites this paper
• Cost effectiveness in the prevention of suicide — A population approach

  2001cites this paper
• Long-term course, comorbidity and long term outcome in depressive disorders.

  2001cites this paper
• Analogues of the potential antipsychotic agent 1192U90: amide modifications.

  1998cites this paper
• Neuroethological assessment of amphetamine-induced behavioral changes and their reversal by neuroleptics: focus on the amygdala and nucleus accumbens.

  1998cites this paper
• Ethnicity and Antipsychotic Response

  1997cites this paper
• Thyrotropin releasing hormone injected into the nucleus accumbens septi selectively increases face grooming in rats.

  1996cites this paper
• Antidepressant-treated Patients in Ambulatory Care

  1996cites this paper
• Antidepressant-Treated Patients in Ambulatory Care

  1996cites this paper
• The long-term management of depression

  1995cites this paper
• Cyclic benzamides as mixed dopamine D2/serotonin 5-HT2 receptor antagonists: potential atypical antipsychotic agents.

  1994cites this paper
• Effects of depot neuroleptics on driving performance in chronic schizophrenic patients.

  1993cites this paper
• A controlled multicenter clinical study of citalopram and placebo in elderly depressed patients with and without concomitant dementia

  1992cites this paper
• The Concept of Supersensitivity Psychosis

  1992cites this paper
• Neue Therapiekonzepte in der Rezidivprophylaxe schizophrener Patienten

  1992cites this paper
• Severe cases of neuroleptic-induced supersensitivity psychosis. Diagnostic criteria for the disorder and its treatment.

  1991cites this paper
• Pharmakologische Aspekte der Neuroleptikawirkung

  1990cites this paper
• Umstellungsregime von Kurzzeit- auf Depotneuroleptika

  1990cites this paper
• Dose finding and serum concentrations of neuroleptics in the treatment of schizophrenic patients.

  1989cites this paper
• Clinical Pharmacology in Psychiatry

  1989cites this paper
• Atypical antipsychotic drugs block selective components of amphetamine-induced stereotypy.

  1988cites this paper
• Antipsychotic drugs in schizophrenia: current issues.

  1988cites this paper